Clinical trials: Meropenem
Complicated Intra-abdominal Infection
Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections
A Phase 2, multicenter, prospective, randomized, double-blind study of CXA-101/ tazobactam (1000/500 mg q8h) and metronidazole (500 mg q8h) IV infusion vs.
- Trial name
- NCT01147640
- Testing
- CXA-101/ tazobactam and metronidazole
- Where
- 33 sites in United States, Argentina and 3 more
- Volunteers
- 122 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Urinary Tract Infections
A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection
This is a non-randomized, open-label, one-treatment, one group study in participants with complicated urinary tract infection (cUTI) including pyelonephritis to characterize the pharmacokinetics of RO7079901 co-administered with…
- Trial name
- NCT03174795
- Testing
- RO7079901, Meropenem
- Where
- 14 sites in United States, Hungary and 3 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Pharmacokinetics Study on Healthy Volunteers Adults
Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants
This is an open-label, non-randomized, single-center, repeated i.v. doses, Phase 1 trial to evaluate the pharmacokinetics, safety, and tolerability of a combination of MEM-ANT3310 in healthy adult female and male participants who…
- Trial name
- NCT06916156
- Testing
- ANT3310, Meropenem
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Antabio
Bacterial Infections
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial…
- Trial name
- TANGOKIDS (NCT02687906)
- Testing
- Vabomere
- Where
- 9 sites in United States
- Volunteers
- 39 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Complicated Intra-Abdominal Infection
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.
- Trial name
- NCT01499290
- Testing
- CAZ-AVI, Metronidazole, Meropenem
- Where
- 56 sites in United States, Argentina and 18 more
- Volunteers
- 493 people
- Sponsor
- Pfizer
Healthy
Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers
This Thorough-QT (TQT) study in healthy volunteers will be conducted in two phases. Phase One will be used to identify a safe supratherapeutic dose to be used in the TQT study (Phase Two).
- Trial name
- NCT03564158
- Testing
- meropenem-vaborbactam, Moxifloxacin
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Pancreatitis, Acute Necrotizing
A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died
This is a research study in patients having a condition known as necrotizing pancreatitis. This is inflammation of the pancreas (an intestinal organ which assists with digestion) that has resulted in the damage and death of some…
- Trial name
- NCT00061438
- Testing
- meropenem
- Where
- 11 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Pfizer
Renal Impairment
Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects
This is an open-label, non-randomized, single-center, single i.v. dose Phase 1 trial to evaluate the pharmacokinetics and safety of a combination of ANT3310 and meropenem in participants with different degrees of renal function…
- Trial name
- NCT06527677
- Testing
- ANT3310, Meropenem
- Where
- Germany
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Antabio
Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia
A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
The purpose of this study is to determine the efficacy, safety, tolerability, and pharmacokinetics (PK) of meropenem-vaborbactam compared to piperacillin/tazobactam for 7 to 14 days in the treatment of hospitalized adults who…
- Conditions
- Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, Hospital-Acquired Pneumonia, Ventilator-Associated Pneumonia
- Trial name
- TANGOIII (NCT03006679)
- Testing
- Meropenem-Vaborbactam, Piperacillin/Tazobactam
- Sponsor
- Melinta Therapeutics, Inc.